319 related articles for article (PubMed ID: 28783976)
1. Mesoporous silica nanorods for improved oral drug absorption.
Zheng N; Li J; Xu C; Xu L; Li S; Xu L
Artif Cells Nanomed Biotechnol; 2018 Sep; 46(6):1132-1140. PubMed ID: 28783976
[TBL] [Abstract][Full Text] [Related]
2. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
[TBL] [Abstract][Full Text] [Related]
3. Lipid-coated hollow mesoporous silica nanospheres for co-delivery of doxorubicin and paclitaxel: Preparation, sustained release, cellular uptake and pharmacokinetics.
Qiu Y; Wu C; Jiang J; Hao Y; Zhao Y; Xu J; Yu T; Ji P
Mater Sci Eng C Mater Biol Appl; 2017 Feb; 71():835-843. PubMed ID: 27987779
[TBL] [Abstract][Full Text] [Related]
4. Multifunctional mesoporous silica nanoparticles modified with tumor-shedable hyaluronic acid as carriers for doxorubicin.
Zhang J; Sun Y; Tian B; Li K; Wang L; Liang Y; Han J
Colloids Surf B Biointerfaces; 2016 Aug; 144():293-302. PubMed ID: 27107383
[TBL] [Abstract][Full Text] [Related]
5. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
[TBL] [Abstract][Full Text] [Related]
6. A surface-grafted ligand functionalization strategy for coordinate binding of doxorubicin at surface of PEGylated mesoporous silica nanoparticles: Toward pH-responsive drug delivery.
Zhang Q; Zhao H; Li D; Liu L; Du S
Colloids Surf B Biointerfaces; 2017 Jan; 149():138-145. PubMed ID: 27750088
[TBL] [Abstract][Full Text] [Related]
7. Biotinylated-lipid bilayer coated mesoporous silica nanoparticles for improving the bioavailability and anti-leukaemia activity of Tanshinone IIA.
Li Z; Zhang Y; Zhang K; Wu Z; Feng N
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):578-587. PubMed ID: 29374971
[TBL] [Abstract][Full Text] [Related]
8. Contribution of carboxyl modified chiral mesoporous silica nanoparticles in delivering doxorubicin hydrochloride in vitro: pH-response controlled release, enhanced drug cellular uptake and cytotoxicity.
Li J; Du X; Zheng N; Xu L; Xu J; Li S
Colloids Surf B Biointerfaces; 2016 May; 141():374-381. PubMed ID: 26878288
[TBL] [Abstract][Full Text] [Related]
9. Polyaspartic acid-anchored mesoporous silica nanoparticles for pH-responsive doxorubicin release.
Hakeem A; Zahid F; Zhan G; Yi P; Yang H; Gan L; Yang X
Int J Nanomedicine; 2018; 13():1029-1040. PubMed ID: 29497295
[TBL] [Abstract][Full Text] [Related]
10. pH and Ultrasound Dual-Responsive Polydopamine-Coated Mesoporous Silica Nanoparticles for Controlled Drug Delivery.
Li X; Xie C; Xia H; Wang Z
Langmuir; 2018 Aug; 34(34):9974-9981. PubMed ID: 30056720
[TBL] [Abstract][Full Text] [Related]
11. Rod-shaped mesoporous silica nanoparticles for nanomedicine: recent progress and perspectives.
Cong VT; Gaus K; Tilley RD; Gooding JJ
Expert Opin Drug Deliv; 2018 Sep; 15(9):881-892. PubMed ID: 30173560
[TBL] [Abstract][Full Text] [Related]
12. pH/H
Wang Y; Wang J; Gou K; Kang W; Guo X; Zhu K; Li S; Li H
ACS Appl Mater Interfaces; 2021 Aug; 13(30):35397-35409. PubMed ID: 34313104
[TBL] [Abstract][Full Text] [Related]
13. Thermo-responsive mesoporous silica/lipid bilayer hybrid nanoparticles for doxorubicin on-demand delivery and reduced premature release.
Zhang Q; Chen X; Shi H; Dong G; Zhou M; Wang T; Xin H
Colloids Surf B Biointerfaces; 2017 Dec; 160():527-534. PubMed ID: 29024917
[TBL] [Abstract][Full Text] [Related]
14. Effects of surface modification and size on oral drug delivery of mesoporous silica formulation.
Wang Y; Cui Y; Zhao Y; Zhao Q; He B; Zhang Q; Wang S
J Colloid Interface Sci; 2018 Mar; 513():736-747. PubMed ID: 29220688
[TBL] [Abstract][Full Text] [Related]
15. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
Shen J; He Q; Gao Y; Shi J; Li Y
Nanoscale; 2011 Oct; 3(10):4314-22. PubMed ID: 21892492
[TBL] [Abstract][Full Text] [Related]
16. A comparison of mesoporous silica nanoparticles and mesoporous organosilica nanoparticles as drug vehicles for cancer therapy.
Yue J; Luo SZ; Lu MM; Shao D; Wang Z; Dong WF
Chem Biol Drug Des; 2018 Aug; 92(2):1435-1444. PubMed ID: 29671941
[TBL] [Abstract][Full Text] [Related]
17. Amphiphilic hyperbranched polyester coated rod mesoporous silica nanoparticles for pH-responsive doxorubicin delivery.
Bafkary R; Ahmadi S; Fayazi F; Karimi M; Fatahi Y; Ebrahimi SM; Atyabi F; Dinarvand R
Daru; 2020 Jun; 28(1):171-180. PubMed ID: 32006342
[TBL] [Abstract][Full Text] [Related]
18. Novel scheme for rapid synthesis of hollow mesoporous silica nanoparticles (HMSNs) and their application as an efficient delivery carrier for oral bioavailability improvement of poorly water-soluble BCS type II drugs.
Li T; Geng T; Md A; Banerjee P; Wang B
Colloids Surf B Biointerfaces; 2019 Apr; 176():185-193. PubMed ID: 30616109
[TBL] [Abstract][Full Text] [Related]
19. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.
Xie X; Li F; Zhang H; Lu Y; Lian S; Lin H; Gao Y; Jia L
Eur J Pharm Sci; 2016 Feb; 83():28-35. PubMed ID: 26690044
[TBL] [Abstract][Full Text] [Related]
20. Development of novel self-assembled ES-PLGA hybrid nanoparticles for improving oral absorption of doxorubicin hydrochloride by P-gp inhibition: In vitro and in vivo evaluation.
Wang J; Li L; Wu L; Sun B; Du Y; Sun J; Wang Y; Fu Q; Zhang P; He Z
Eur J Pharm Sci; 2017 Mar; 99():185-192. PubMed ID: 27989702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
